Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ocular Therapeut (NQ: OCUL ) 10.78 -0.16 (-1.46%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ocular Therapeut < Previous 1 2 Next > R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments May 02, 2023 EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences November 08, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update November 07, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results October 24, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD September 27, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting September 22, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 07, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference August 10, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update August 08, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results July 25, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases June 08, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference June 01, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update May 09, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting May 03, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Report First Quarter 2022 Financial Results April 26, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting April 25, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting April 14, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results February 22, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360 February 11, 2022 From Ocular Therapeutix, Inc. Via Business Wire AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients January 18, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference January 04, 2022 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease December 06, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences November 15, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc. November 09, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update November 08, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA® November 05, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021 November 01, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results October 29, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting October 28, 2021 From Ocular Therapeutix Via Business Wire Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint October 22, 2021 From Ocular Therapeutix, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
